Development of vaccines for high-risk ductal carcinoma in situ of the breast

Cancer Research

Volumn 67, Issue 14, 2007, Pages 6531-6534

  Czerniecki, Brian J ^a   Roses, Robert E ^a   Koski, Gary K ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADAPTIVE IMMUNITY; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CARCINOMA IN SITU; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DUCTAL CARCINOMA IN SITU; GENE OVEREXPRESSION; GENE TARGETING; HIGH RISK PATIENT; HUMAN; INNATE IMMUNITY; INTRADUCTAL CARCINOMA; PARTIAL MASTECTOMY; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; TREATMENT OUTCOME; VACCINATION;

BREAST NEOPLASMS; CANCER VACCINES; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DENDRITIC CELLS; DISEASE PROGRESSION; HUMANS; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; RECEPTOR, ERBB-2;

EID: 34547136715     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0878     Document Type: Review

References (20)

1. Silverstein MJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 1999;340:1455-61.
2. Fisher ER, Dignam J, Tan-Chiu E, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer 1999;86:429-38.
3. Hwang ES, Esserman L. Neoadjuvant hormonal therapy for ductal carcinoma in situ: trial design and preliminary results. Ann Surg Oncol 2004;11:37-43S.
4. Gonzalez RJ, Buzdar AU, Fraser Symmans W, et al. Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin). Breast J 2007;13:72-5.
5. Czerniecki BJ, Koski GK, Koldovsky U, et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 2007;67:1842-52.
6. Kerlikowske K, Barclay J, Grady D, Sickles EA, Ernster V. Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. J Natl Cancer Inst 1997;89:76-82.
7. Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer 2001;8:47-61.
8. Barnes NLP, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res 2005;11:2163-8.
9. Nofech-Mozes S, Spayne J, Kahn HJ, et al. Is HER2/neu a predictor for invasive recurrence in DCIS [abstract 1118]. 29th Annual San Antonio Breast Cancer Symposium, December 14, 2006, San Antonio, Texas.
10. + Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J Immunol 2005;174:4228-36.
11. Nanni P, Landuzzi L, Nicoletti G, et al. Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-γ and B cell dependent. J Immunol 2004;173:2288-96.
12. + T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol 2003;171:2251-61.
13. + T cell responses in vitro. J Immunother 2007;30:75-82.
14. Disis ML, Gooley TA, Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002;20:2624-32.
15. Murray JL, Gillogly ME, Przepiorka D, et al. Toxicity, immunogenicity, and induction of E75-specific tumorlytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 2002;8:3407-18.
16. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
17. Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 2004;82:249-93.
18. + regulatory T cells and their ligands: implications for immunotherapy. Immunity 2004;20:107-18.
19. Kusmartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 2006;55:237-45.
20. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004;4:762-74.